Brighton Jones’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.94M Sell
7,527
-521
-6% -$267K 0.07% 184
2026
Q2
$4M Buy
8,048
+1,292
+19% +$573K 0.07% 178
2026
Q1
$3.02M Buy
+6,756
New +$3.15M 0.07% 206
2025
Q4
– Sell
-4,693
Closed -$1.84M – 943
2025
Q3
$1.84M Buy
4,693
+134
+3% +$56K 0.04% 237
2025
Q2
$2.03M Sell
4,559
-1,862
-29% -$858K 0.06% 190
2025
Q1
$3.11M Buy
6,421
+1,994
+45% +$929K 0.1% 119
2024
Q4
$1.78M Buy
4,427
+579
+15% +$268K 0.05% 181
2024
Q3
$1.79M Sell
3,848
-452
-11% -$217K 0.07% 144
2024
Q2
$2.02M Buy
4,300
+3,171
+281% +$1.38M 0.07% 150
2024
Q1
$472K Buy
1,129
+194
+21% +$82K 0.02% 360
2023
Q4
$380K Sell
935
-129
-12% -$47.7K 0.02% 387
2023
Q3
$370K Buy
1,064
+45
+4% +$15.7K 0.02% 353
2023
Q2
$359K Buy
1,019
+60
+6% +$20.2K 0.02% 363
2023
Q1
$302K Buy
959
+85
+10% +$25.5K 0.02% 375
2022
Q4
$252K Sell
874
-369
-30% -$112K 0.02% 381
2022
Q3
$360K Buy
1,243
+369
+42% +$106K 0.02% 300
2022
Q2
$246K Buy
874
+29
+3% +$7.76K 0.01% 374
2022
Q1
$221K Buy
+845
New +$201K 0.01% 454

Other funds holding VRTX

Brighton Jones's VRTX Position: Q3 2026 in Review

Brighton Jones reduced its Vertex Pharmaceuticals (VRTX) stake by 6.5% in Q3 2026, selling an estimated $267K and leaving 7,527 shares worth $3.94M. The position accounts for 0.07% of the portfolio, ranked #184.

Brighton Jones first reported a position in VRTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $4M in Q2 2026. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Brighton Jones held 7,527 shares of Vertex Pharmaceuticals worth $3.94M as of Q3 2026.
  • Brighton Jones sold 521 Vertex Pharmaceuticals shares in Q3 2026, an estimated $267K.
  • Vertex Pharmaceuticals made up 0.07% of Brighton Jones's portfolio in Q3 2026, its #184 holding.
  • Brighton Jones first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Brighton Jones's Vertex Pharmaceuticals position peaked at $4M in Q2 2026.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.